| Literature DB >> 29720968 |
Meeta Masand1, Kunjukrishnan Kamalakshi Sivakala2, Ekta Menghani3, Thangathurai Thinesh4, Rangasamy Anandham5, Gaurav Sharma1, Natesan Sivakumar2, Solomon R D Jebakumar2, Polpass Arul Jose2.
Abstract
Acquisition of Actinobacteria, especially Streptomyces from previously underexplored habitats and the exploration of their biosynthetic potential have gained much attention in the rejuvenated antibiotics search programs. Herein, we isolated some Streptomyces strains, from an arid region of the Great Indian Thar Desert, which possess an ability to produce novel bioactive compounds. Twenty-one morphologically distinctive strains differing in their aerial and substrate mycelium were isolated by employing a stamping method. Among them, 12 strains were identified by a two-level antimicrobial screening method, exerting antimicrobial effects against a panel of indicator strains including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus species. Based on their potent antimicrobial activity, four isolates were further explored by 16S rRNA gene-based identification, genetic screening, and metabolomic analysis; and it was found that these strains belong to the genus Streptomyces. The selected strains were found to have polyketide synthase and non-ribosomal peptide synthetase systems. In addition, extracellular metabolomic screening revealed that the isolates produced analogs of doxorubicinol, pyrromycin, erythromycin, and 6-13 other putative novel metabolites. These results demonstrate the significance of Streptomyces inhabiting the arid region of Thar Desert, suggesting that similar arid environments can be considered as the reservoirs of novel Streptomyces strains that could have biotechnological significance.Entities:
Keywords: Streptomyces; antimicrobial activity; arid; desert; metabolomics; secondary metabolome
Year: 2018 PMID: 29720968 PMCID: PMC5915549 DOI: 10.3389/fmicb.2018.00687
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers used in PCR-based screening of isolates for PKS and NRPS biosynthetic systems.
| Gene | Primer (5′ to 3′) | Reference |
|---|---|---|
| PKS-ketosynthase domain | TSGCSTGCTTGGAYGCSATC (F) | |
| NRPS-adenylation domain | GCSTACSYSATSTACACSTCSGG (F) |
Morphological characteristics of actinobacterial isolates acquired from the desert soils.
| Isolates | Aerial mycelium | Substrate mycelium | Pigmentation |
|---|---|---|---|
| SAS01 | Dark pink with gray spores | pink | Dark pink |
| SAS02 | Creamy white with white spores | Light yellow | No |
| SAS03 | Red with gray spores | Red | Red |
| SAS04 | White | White | Yellow |
| SAS05 | White | White | No |
| SAS06 | White | Yellow | Pale yellow |
| SAS07 | Yellow with dark gray spores | Yellow | No |
| SAS08 | White | Yellowish white | Yellowish orange |
| SAS09 | Gray | white | No |
| SAS10 | Gray | Gray | Brown |
| SAS11 | White | Pale yellow | No |
| SAS12 | White pinpoint colonies | White | No |
| SAS13 | White | Light pink | Light pink |
| SAS14 | Yellow | Yellow | No |
| SAS15 | Gray | Light pink | Light brownish |
| SAS16 | Orange with white spores | Orange | Pale orange |
| SAS17 | White and dark blue | Dark blue | No |
| SAS18 | White | White | No |
| SAS19 | Orange | Orange | Yellow |
| SAS20 | White | White | No |
| SAS21 | Pale pink | Pale pink | No |
Antimicrobial activity of active isolates against both clinical and ATCC strains.
| Isolates | Media | Antimicrobial activity (diameter of inhibition halo in mm ± SD) | ||||
|---|---|---|---|---|---|---|
| Vancomycin-resistant | Methicillin-resistant | |||||
| SAS01 | ISP4 | – | 12 ± 1.52 | 12 ± 1.00 | – | – |
| SCA | – | 12 ± 1.00 | 16 ± 0.57 | 12 ± 1.52 | 14 ± 0.57 | |
| SAS02 | ISP4 | 16 ± 1.52 | 15 ± 0.00 | 14 ± 0.057 | 16 ± 1.73 | 16 ± 1.15 |
| SCA | 18 ± 0.00 | 14 ± 2.00 | 15 ± 2.00 | 17 ± 1.00 | 16 ± 0.57 | |
| SAS03 | ISP4 | – | – | 18 ± 1.52 | 13 ± 2.51 | – |
| SCA | – | – | – | – | 18 ± 0.00 | |
| SAS04 | ISP4 | – | 14 ± 2.51 | – | 13 ± 2.00 | – |
| SCA | – | 9 ± 0.57 | – | – | 13 ± 0.00 | |
| SAS05 | ISP4 | 15 ± 1.52 | 18 ± 0.57 | 14 ± 1.52 | 17 ± 0.00 | 17 ± 1.52 |
| SCA | 18 ± 0.57 | 8 ± 0.57 | 14 ± 1.15 | 12 ± 1.52 | 9 ± 0.00 | |
| SAS06 | ISP4 | – | 20 ± 1.00 | 22 ± 2.00 | 22 ± 1.00 | – |
| SCA | – | 20 ± 1.52 | 13 ± 1.73 | 19 ± 0.00 | 22 ± 2.51 | |
| SAS08 | ISP4 | – | – | 17 ± 0.57 | 20 ± 2.08 | – |
| SCA | – | – | – | – | – | |
| SAS09 | ISP4 | 15 ± 1.52 | 14 ± 0.00 | 28 ± 1.00 | 30 ± 1.15 | 24 ± 1.15 |
| SCA | 16 ± 0.57 | 16 ± 0.57 | 16 ± 2.51 | 22 ± 1.52 | 15 ± 0.00 | |
| SAS11 | ISP4 | – | 18 ± 2.00 | 15 ± 0.57 | – | – |
| SCA | – | – | – | – | – | |
| SAS13 | ISP4 | 16 ± 0.00 | 18 ± 0.00 | 17 ± 2.00 | 18 ± 1.52 | 26 ± 0.57 |
| SCA | 18 ± 2.00 | 22 ± 0.57 | 15 ± 0.57 | 14 ± 0.57 | – | |
| SAS15 | ISP4 | 18 ± 1.00 | 22 ± 0.00 | 21 ± 0.57 | 24 ± 2.51 | 20 ± 0.57 |
| SCA | 20 ± 2.00 | 22 ± 3.51 | 20 ± 0.00 | 18 ± 2.00 | 15 ± 1.00 | |
| SAS19 | ISP4 | 16 ± 0.57 | 18 ± 1.00 | 18 ± 0.00 | 19 ± 0.57 | 19 ± 2.00 |
| SCA | 16 ± 1.00 | 22 ± 2.51 | 22 ± 2.00 | 24 ± 0.00 | 21 ± 0.57 | |
16S rRNA gene sequence data in comparison with nearest valid members of Streptomyces genus.
| Isolate | 16S gene data coverage (bp) | Accession number | Maximum similarity (%) | Nearest type strain |
|---|---|---|---|---|
| SAS02 | 1,396 | KP986569 | 98.35 | |
| SAS09 | 1,390 | KP986570 | 99.93 | |
| SAS13 | 1,391 | KP986571 | 99.86 | |
| SAS15 | 1,375 | KP986572 | 100.0 |
Known and putatively novel secondary metabolites found from the selected isolates in chemical analysis.
| Isolate | Known secondary metabolites | Putatively novel secondary metabolites | |||
|---|---|---|---|---|---|
| Nos. | Mass (m/z) and related compounds∗ | Structural class and activity | Nos. | Mass (m/z) | |
| SAS02 | 1 | [M+H]+ = 568.1903 Doxorubicinol | Anthracyclines, anticancer activity | 12 | [M+H]+ = 135.0182, 146.032, 174.0224, 129.0087, 254.0471, 265.0616, 489.2129, 265.0617, 449.1854, 489.2149, 526.1938, 537.2806 |
| SAS09 | 2 | [M+H]+ = 568.2139 Pyrromycin | Anthracycline glycoside, antibacterial activity | 5 | [M+H]+ = 120.0145, 191.0056, 322.03, 852.3207, 812.3345 |
| [M+H]+ = 790.4954 Erythromycin | Macrolide, antibacterial activity | ||||
| SAS13 | 2 | [M+H]+ = 568.2149 Pyrromycin | Anthracycline glycoside, antibacterial activity | 6 | [M+H]+ = 129.9969, 147.0222, 550.1804, 731.4479, 376.2484, 825.3443 |
| [M+H]+ = 790.4945 Erythromycin | Macrolide, antibacterial activity | ||||
| SAS15 | 1 | [M+H]+ = 746.4712 14-hydroxy-6-omethylerythromycin A | Macrolide, antibacterial activity | 9 | [M+H]+ = 210.082, 590.2232, 337.0776, 111.0018, 618.2537, 279.0547, 640.5538, 616.3332, 657.418 |